Key Takeaways
- Australia’s S&P/ASX 200 index surged 0.9% to close at a record high of 9,227.80 points, driven by strong performance in the mining and financial sectors.
- Glencore (GLEN) reported robust H1 2026 earnings with an adjusted EBITDA of $10.12 billion, beating estimates and announcing a new $500 million share buyback.
- Legal & General (LGEN) posted an operating profit of £918 million, slightly ahead of expectations, and signaled it expects full-year EPS growth to exceed its 6-9% target range.
- Ryanair (RYA) achieved record July traffic of 22.2 million passengers, marking a 7% year-on-year increase while maintaining a high load factor of 96%.
- European equity futures point to a positive open, with DAX and Euro Stoxx 50 futures rising as investors digest a heavy slate of corporate earnings and economic data.
Corporate Earnings and Market Movers
Glencore (GLEN) delivered a strong first-half performance for 2026, reporting adjusted EBIT of $6.65 billion and revenue of $174.43 billion, both significantly ahead of analyst estimates. The commodities giant announced total shareholder returns of approximately $3.5 billion for the year, including a new $500 million share buyback program. Additionally, the company confirmed plans to apply for a secondary listing on the ASX, aiming to tap into Australian capital markets.
Legal & General (LGEN) reported H1 2026 operating profits of £918 million, beating the consensus estimate of £917 million. Despite Assets Under Management (AUM) coming in at £1.12 trillion—slightly below the £1.2 trillion forecast—the insurer remains optimistic. Management stated that FY26 Core Operating EPS is expected to land above the top end of its 6-9% target range, noting the firm is on track to meet or exceed all strategic targets.
Ryanair (RYA) continues to see surging demand for low-cost travel, reporting a record 22.2 million guests in July. This represents a 7% increase compared to the previous year, with the rolling 12-month passenger count now reaching 213.2 million. The airline maintained a 96% load factor, suggesting that capacity increases are being met with consistent consumer appetite despite broader economic pressures.
Global Macroeconomic Trends
In the Asia-Pacific region, the S&P/ASX 200 reached a historic milestone, closing at 9,227.80 points. This record-breaking session reflects investor confidence in the region's resilience. Meanwhile, South Korean officials are engaged in a flurry of diplomatic activity; the Foreign Minister noted that while multilateral talks with North Korea remain "realistically difficult," Seoul is coordinating closely with Washington on nuclear enrichment issues and with China on regional stability.
European economic indicators showed some cooling in the Nordic region. Sweden’s Swedbank/Silf PMI Composite fell to 54.7 in July from 57.1 in June, while the Services PMI dipped to 54.2. Although these figures remain in expansionary territory (above 50), the decline suggests a softening in the pace of growth for the Swedish service sector.
In Russia, the S&P Global Services PMI for July edged up to 49, compared to 48.2 in June. While the index shows slight improvement, it remains in contraction territory. The Composite PMI followed a similar trend, rising to 49.6, indicating that the Russian private sector is still struggling to find a path back to growth amid ongoing geopolitical constraints.
Analyst Updates and Tech Moves
Rolls-Royce (RR) received a significant vote of confidence from Deutsche Bank, which raised its price target for the engineering firm to 1,705p from 1,325p. The upgrade reflects optimism regarding the company's turnaround strategy and long-term engine flying hour recovery.
In the private equity and space sector, SpaceX shares listed on the Tradegate exchange dropped 7%. This move aligns with recent U.S. after-hours trading activity, as markets react to broader volatility in high-growth tech valuations. Separately, Novo Nordisk (NVO) CEO Lars Fruergaard Jørgensen reiterated confidence in the company’s R&D platform, emphasizing the strength of its obesity and diabetes drug pipeline.
Ed Liston is a senior contributing editor at TheStockMarketWatch.com. An active market watcher and investor, Ed guides an independent team of experienced analysts and writes for multiple stock trader publications.